Information Provided By:
Fly News Breaks for February 12, 2020
Feb 12, 2020 | 18:10 EDT
Goldman Sachs analyst Amit Hazan initiated coverage of Edwards Lifesciences with a Neutral rating and $253 price target. The analyst sees some upside to consensus 2020 sales and earnings estimates given the continued strong growth in U.S. TAVR adoption, with added capital flexibility further supporting the stock. Beyond 2020 however, Hazan is "much more cautious" on TAVR and Mitral contribution for Edwards Lifesciences, supporting his neutral stance.
News For EW From the Last 2 Days
There are no results for your query EW